Modified methodology for obtaining material of peripheral lung tumors with EBUS-GS

Histological verification of peripheral neoplasms of the lungs is an actual problem of modern oncology. The use of the method of EBUS-GS increased the possibility of establishing a diagnosis in the outpatient stage from 30 to 85% of patients. The aim of the research is to increase the percentage of verification when the ultrasound probe is located in the pathological focus, but on the border with the unchanged lung parenchyma, by the modification of the distal tip of the standard guiding sheath for "controlled" opening of the biopsies to the center of the pathological focus.Гистологическая верификация периферических новообразований легких является актуальной проблемой современной онкологии. Применение метода ультразвуковой бронхоскопии с использованием направляющей оболочки значительно расширило возможность установления диагноза на амбулаторном этапе от 30 до 85% пациентов. Целью работы является повысить процент верификации при расположении ультразвукового зонда в патологическом очаге, но на границе с неизменённой паренхимой лёгкого с помощью модификации дистального кончика стандартного тубуса-проводника для "контролируемого" раскрытия бранш биопсийных в сторону центра паталогического очага

РЕЗУЛЬТАТЫ СОЧЕТАННОЙ ЛУЧЕВОЙ ТЕРАПИИ РАКА ПИЩЕВОДА С ПРИМЕНЕНИЕМ БРАХИТЕРАПИИ ВЫСОКОЙ МОЩНОСТИ

Between 2008 and 2015, 82 patients with inoperable esophageal cancer were treated with radiation therapy. The patients were divided into 3 groups. Group I consisted of 30 patients, who received external beam radiation therapy (EBRT) in combination with brachytherapy. Group II and group III patients (30 and 22 patients, respectively) received EBRT alone. Patients of group II received EBRT at a total dose of 60–70 Gy and patients of group III received EBRT at a total dose of 40–50 Gy. Treatment outcomes were better in patients treated with combination of EBRT and brachytherapy than in patients treated with EBRT alone. There was no significant difference between groups 2 and 3 with regard to their survival rates. Two-year overall survival rates in group I, II and III were 36 %, 12 % and 12 % and the median overall survival time was 15.7; 9.7 and 6.6 months, respectively.Проведено сравнительное исследование с включением 82 пациентов, страдающих раком пищевода, получивших самостоятельный курс лучевой терапии. В первую группу вошли 30 пациентов, получивших сочетанную лучевую терапию с брахитерапией, во 2-ю группу – 30 пациентов, получивших дистанционную лучевую терапию (ДЛТ) до суммарной дозы 60–70 Гр, у 22 пациентов 3-й группы суммарная доза ДЛТ была ограничена 40–50 Гр. Результаты лечения оказались лучше в группе сочетанной лучевой терапии, в то время как значение суммарной дозы ДЛТ не повлияло на показатели выживаемости. Двухлетняя общая выживаемость в сравниваемых группах составила 36, 12 и 12 %, медиана общей выживаемости – 15,7; 9,7 и 6,6 мес соответственно.

TREATMENT OUTCOMES OF EXTERNAL BEAM RADIOTHERAPY COMBINED WITH HIGH-DOSE-RATE BRACHYTHERAPY IN PATIENTS WITH ESOPHAGEAL CANCER

Between 2008 and 2015, 82 patients with inoperable esophageal cancer were treated with radiation therapy. The patients were divided into 3 groups. Group I consisted of 30 patients, who received external beam radiation therapy (EBRT) in combination with brachytherapy. Group II and group III patients (30 and 22 patients, respectively) received EBRT alone. Patients of group II received EBRT at a total dose of 60–70 Gy and patients of group III received EBRT at a total dose of 40–50 Gy. Treatment outcomes were better in patients treated with combination of EBRT and brachytherapy than in patients treated with EBRT alone. There was no significant difference between groups 2 and 3 with regard to their survival rates. Two-year overall survival rates in group I, II and III were 36 %, 12 % and 12 % and the median overall survival time was 15.7; 9.7 and 6.6 months, respectively